WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 57,500 restricted stock units of Arcutis' common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis' Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, wit ...

Arcutis Biotherapeutics, Inc. (ARQT) closed the last trading session at $9.20, gaining 1.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $18.50 indicates a 101.1% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $4.81. While the lowest estimate of $11 indicates a 19.6% increase from the current price level, the most optimisti ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank Watanabe - President and Chief Executive Officer Todd Edwards - Chief Commercial Officer Patrick Burnett - Chief Medical Officer David Topper - Chief Financial Officer Conference Call Participants Serge Belanger - Needham Seamus Fernandez - Guggenheim Securities Vikram Purohit - Morgan Stanley Tyler Van Buren - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q 91361 (Zip Code) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other ...

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update • First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '23 and 59% vs. Q4 '23 • Continued gross-to-net (GTN) improvement with blended GTN across products now in the low 60 percent range • Sustained growth in demand for cream and remarkable uptake of foam launched in January • July 7 ...

Core Insights - ZORYVE foam, a topical treatment for seborrheic dermatitis, has received strong endorsement from an expert dermatologist panel, indicating its suitability for diverse skin and hair types [1][3] - The formulation of ZORYVE foam is designed to be gentle and free from harmful ingredients, making it a versatile option for patients with various hair care practices [2][3] - ZORYVE foam is the first drug with a new mechanism of action approved for seborrheic dermatitis in over two decades, targeting the underlying inflammatory processes [5] Company Overview - Arcutis Biotherapeutics, Inc. is focused on developing innovative treatments for immune-mediated dermatological diseases, with a growing portfolio that includes FDA-approved products [8] - The company aims to address persistent patient challenges in dermatology through its unique development platform and expertise [8] Product Details - ZORYVE foam (roflumilast) is indicated for the treatment of seborrheic dermatitis in patients aged 9 years and older [6] - The foam formulation is a once-daily, steroid-free treatment that effectively delivers therapeutic agents to affected areas, including the scalp [1][5] - The formulation includes Crodafos CES, a gentle emulsifier that enhances compatibility with various skin and hair types [2][3]

Group 1 - Arcutis Biotherapeutics, Inc. will report its first quarter 2024 financial results and provide a business update on May 14, 2024, after U.S. financial markets close [1] - A conference call and webcast will be held on the same day at 4:30 p.m. ET, with a live webcast available on the company's website [1] - An archived replay of the webcast will be accessible on the Arcutis investor website following the conference call [1] Group 2 - Arcutis Biotherapeutics is a commercial-stage medical dermatology company focused on innovations for immune-mediated dermatological diseases [2] - The company has two FDA-approved products and a growing portfolio that addresses persistent patient challenges in dermatology [2] - Arcutis' development platform includes a robust pipeline with multiple clinical programs targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [2]

Core Viewpoint - The stock price of Arcutis Biotherapeutics, Inc. (ARQT) has been on a bearish trend, losing 6.5% over the past two weeks, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1]. Technical Analysis - The hammer chart pattern indicates a potential bottom formation, suggesting that selling pressure may be subsiding [1][3]. - A hammer pattern typically forms during a downtrend when the stock opens lower, makes a new low, but then closes near or above the opening price, indicating a shift in control from bears to bulls [2][3]. Fundamental Analysis - There has been a significant upward trend in earnings estimate revisions for ARQT, with the consensus EPS estimate increasing by 6% over the last 30 days, indicating strong agreement among analysts about improved earnings potential [4]. - The Zacks Rank for ARQT is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which historically outperform the market [5].

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows significant potential for upside, with a mean price target of $16.50 indicating a 54.8% increase from the current price of $10.66, despite recent gains of 14.6% over the past four weeks [1] Price Targets and Analyst Consensus - The mean price target consists of six short-term estimates with a standard deviation of $6.44, suggesting variability in analyst opinions; the lowest estimate is $8 (25% decline), while the highest is $26 (143.9% increase) [1] - Analysts' price targets are often viewed with skepticism due to potential biases and inflated estimates driven by business relationships [3][4] Earnings Estimates and Market Sentiment - Analysts are optimistic about ARQT's earnings prospects, as indicated by a 6% increase in the Zacks Consensus Estimate for the current year, with two estimates revised upward and no negative revisions [5] - The company holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for near-term upside [5]

Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement across multiple efficacy endpoints as early as Week 139.4% of children treated with roflumilast cream 0.05% achieved a 75% improvement in Eczema Area and Severity Index (EASI-75), a key secondary endpointNew data highlight rapid and significant reduction in itch as early as 24 hours following first application of roflumilast cream 0.05% based on daily Worst Itch Numeric Scale (WI-NRS ...